Experimental cell therapy tested in 3 ALS patients
NCT ID NCT03241784
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tested whether infusing a patient's own regulatory T cells (immune-calming cells) along with interleukin-2 injections is safe for people with ALS. Only 3 participants were enrolled, and the main goal was to check for side effects. The approach aims to slow disease progression by reducing immune system attacks on nerve cells.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- T-regulatory cells and interleukin-2 (IL-2)
- What this could lead to
- If successful, this could point toward a way to slow ALS progression by calming the immune system.
- What could go wrong
- This is a very early, tiny phase 1 safety trial with only 3 participants. It cannot prove effectiveness, and side effects or lack of benefit are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Methodist Neurological Institute
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood markers may unlock early ALS detection — a study puts them to the test
- Brain implant aims to give voice to those trapped in silence
- Nasal spray aims to tame brain inflammation in ALS
- Robotic arm could help people with paralysis regain independence at home
- Gene therapy injection hopes to slow ALS
- Super-Sharp brain scanner could revolutionize diagnosis of dementia and cancer